Indrayani Biotech Rights Issue 2026: Dates, Price

What the company has announced

Indrayani Biotech has announced a rights issue to raise funds, with key terms such as the record date, issue price, entitlement ratio, and use of proceeds disclosed. The company has fixed April 28, 2026 as the record date to determine shareholder eligibility. The rights issue price is ₹15 per equity share, and each share has a face value of ₹10. The entitlement ratio is 5:7, meaning eligible shareholders can apply for 5 rights equity shares for every 7 fully paid-up equity shares held on the record date.

The rights issue has been described as a ₹49.90 crore issue in company-related disclosures, and also as approximately ₹48.79 crore in the offer details section, reflecting slightly different figures cited across the provided material. The issue is proposed to be listed on BSE.

Record date and last date to buy shares

The record date matters because rights entitlements are determined based on holdings as of that date. Indrayani Biotech’s record date is stated as Tuesday, April 28, 2026. The material also specifies April 27, 2026 as the last date to buy shares for eligibility.

For investors, this timeline is important because buying shares after the last eligible date would typically not confer rights entitlement for this issue under the stated schedule. The entitlement ratio of 5:7 is repeatedly confirmed across the details provided.

Issue price, face value, and premium

The issue price has been set at ₹15 per share. The company has also clarified that this includes ₹10 face value plus ₹5 premium. This breakdown is relevant for understanding the structure of the partly paid-up rights shares and how payments are split between application money and later calls.

The rights issue is described as comprising 3,25,25,897 equity shares (over 3.25 crore shares). In the detailed committee update, these are described as partly paid-up equity shares priced at ₹15 per share when fully paid up.

Partly paid-up structure and payment schedule

Indrayani Biotech has opted for a partly paid-up rights issue structure. Under the phased payment plan stated in the material:

• ₹3.75 per share is payable on application
• The remaining ₹11.25 per share is payable through one or more calls, as determined by the Rights Issue Committee later

The initial application amount of ₹3.75 is further described as covering ₹2.50 of face value and ₹1.25 of premium. This structure can affect how entitlements trade (where applicable) and how investors plan cash outflows, since the full ₹15 is not paid upfront.

Key dates: original schedule and revised schedule

The provided information includes two sets of timelines.

One schedule states the rights issue will open on May 27, 2026 and close on June 25, 2026, with on-market renunciation permitted until June 16, 2026. Separately, an update states the issue will now remain open from June 25, 2026 to July 24, 2026, with the last date for on-market renunciation set for July 20, 2026. The same update also notes the company confirmed that other terms remain unchanged, and revised documents will be available on the BSE website and the company website.

Because both schedules appear in the provided material, investors typically rely on the latest company communication and the updated Letter of Offer filings for final operational dates.

Snapshot of the offer terms

How the company plans to use the proceeds

The company has disclosed proposed utilisation of net proceeds across working capital, loan and advance set-offs, and general corporate purposes. The table below is stated in the material as the object-wise estimate.

Renunciation and shareholder options

The material highlights that shareholders who do not wish to subscribe can renounce or trade rights entitlements during the specified renunciation window. It mentions an on-market renunciation period aligned with the issue window (with dates given as May 27 to June 16, 2026 under one schedule, and up to July 20, 2026 under the revised schedule). It also notes off-market renunciation must be completed in time for entitlements to be credited before the issue closes.

These options matter because the entitlement ratio (5:7) can create fractional planning decisions for investors with non-multiples of 7 shares, depending on the entitlement credit and trading mechanics outlined in the Letter of Offer.

Where to apply and whom to contact

The issue can be applied for via Net Banking (ASBA) or through the Registrar’s website (R-WAP facility), as stated. The registrar is MUFG Intime India Pvt. Ltd. with contact details provided: +91-22-4918 6270 and indrayani.rights@in.mpms.mufg.com, and a public issues webpage link is included in the material.

Company contact details are also provided for Indrayani Biotech Ltd at Block 1, 33, SIDCO Electronic Complex, Thiru Vi Ka Industrial Estate, Guindy, Chennai 600032, with Phone: 914424463751 and Email: info@indrayani.com.

Why this rights issue matters for investors

For existing shareholders, the announcement sets a clear eligibility cut-off through the April 28, 2026 record date and defines the cost of participation at ₹15 per share, with ₹3.75 payable upfront under the partly paid structure. The entitlement ratio of 5 rights shares for every 7 shares held indicates the potential dilution for non-participating shareholders and the opportunity for participating shareholders to increase ownership by subscribing to their entitlement and any additional shares if permitted.

The disclosed utilisation plan also shows the issue is not only for working capital but also includes set-offs against promoter loan and an unsecured advance from Bougainvillea Investments Private Limited (BIPL) through share allotment at the rights issue price, along with general corporate purposes.

Conclusion

Indrayani Biotech’s rights issue is anchored by the April 28, 2026 record date, a ₹15 issue price, and a 5:7 entitlement ratio, with the issue structured as partly paid-up shares requiring ₹3.75 on application and the remainder through calls. Key dates have been presented in both an original and revised schedule, and the company has stated that aside from the adjustments to opening, closing, and renunciation dates, other terms remain unchanged. Investors tracking the offer will typically look to the revised LOF/ALOF/CAF and BSE postings for the final operational timeline.